GradedHealth

Does psilocybin help depression? A 2026 meta-analysis finds large symptom drops, with caveats

A 2026 meta-analysis found large drops in depression scores after psilocybin plus therapy; earlier reviews show a medium edge over placebo.

Published October 2026

Short answer

Yes. Psilocybin plus supportive therapy lowered depression scores, with a medium edge over placebo in earlier reviews. Trials are small and hard to blind, and a 2026 trial missed its main goal. Evidence grade C (Limited). Several meta-analyses of small randomised trials agree on a benefit; downgraded for small total samples, risk of bias from unblinding, and inconsistency, including a 2026 trial that missed its primary end point.

Key takeaways

  • A 2026 meta-analysis found a large fall in depression symptoms from baseline with psilocybin plus supportive therapy (standardised change -1.24, 95% CI -1.83 to -0.65) and a greater fall than with placebo (p = 0.032), though results varied widely between studies [1].
  • Earlier reviews agree: a 2024 BMJ review of seven trials (436 people) found a medium edge over placebo or non-psychoactive comparators (Hedges' g 0.66, 95% CI 0.46 to 0.86) [2], and a 2025 review of six trials found response and remission more than three times as likely up to six weeks (risk ratios 3.42 and 3.66) [3].
  • Not every trial agrees: the 144-person EPISODE trial in treatment-resistant depression missed its primary target, with response in 17.0% on 25 mg versus 10.6% on a placebo pill [4].
  • Participants can often tell they have had the drug, and control groups in psilocybin trials improved less than in SSRI or esketamine trials, so the benefit may be overestimated [5].
  • Side effects include headache and dizziness [3], and in EPISODE suicidal ideation on dosing days was more common with 25 mg (4% vs 1% to 2%) [4].

What the study did

This 2026 systematic review and meta-analysis searched Medline and the Cochrane Library for randomised trials of psilocybin for depression. The authors used a multilevel model to estimate the overall effect, comparing symptoms before and after psilocybin plus supportive therapy, and also compared the change with placebo [1]. They also looked at how the effect changed over time after dosing [1].

What it found

Depression symptoms fell by a large amount: a standardised change of -1.24 (95% CI -1.83 to -0.65) from baseline, with a clinically noticeable reduction. The fall was also greater than with placebo (p = 0.032), and it stayed significant across the time intervals analysed [1]. Results differed a lot between studies, with a high level of heterogeneity between the studies' effects (I2 about 78%) [1].

How it fits

Earlier reviews point the same way. A 2024 BMJ meta-analysis of seven trials (436 people) found psilocybin beat placebo or non-psychoactive comparators (Hedges' g 0.66), and all included studies had a moderate risk of bias [2]. A 2025 review of six trials found larger response and remission rates, but more headache (risk ratio 1.78) and dizziness (6.52) [3]. Another 2026 review of seven trials (522 people) found a large effect and hinted that weight-based dosing and longer therapy sessions did better, although those subgroup differences were not statistically significant [6].

The picture is less clear in the biggest recent trial. The 144-person EPISODE trial in treatment-resistant depression gave two doses with psychotherapy, and the primary response measure at week 6 was not significantly better with 25 mg (17.0%) than with a nicotinamide placebo (10.6%) [4]. Secondary measures offered exploratory evidence of a clinically meaningful effect, and the authors called the trial inconclusive [4].

See the Psilocybin page for the full evidence on depression, anxiety in serious illness and alcohol use.

Limits

The headline figure compares people with their own starting scores, which cannot separate the drug from expectation or natural improvement; the placebo comparison is the stronger test [1]. The abstract's conclusion that psilocybin beats psychotherapy alone goes further than the trials it describes, and the authors call for larger and longer studies [1]. A 2025 meta-analysis found people in control groups of psilocybin trials improved less than controls in SSRI and esketamine trials, which may mean psilocybin's benefit is overestimated [5]. In EPISODE, suicidal ideation on dosing days was reported by 4% on 25 mg versus 1% to 2% in the comparison groups, and two serious adverse reactions followed 25 mg, including one case of hallucinogen persisting perception disorder [4]. Trials gave psilocybin with psychotherapy in clinical settings [4]. This is not medical advice; anyone with depression should talk to their doctor before changing treatment.

Go deeper

  • Psilocybin — In supervised trials, psilocybin-assisted therapy reduces depression symptoms quickly, with effects often lasting weeks to months.

References

  1. Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.. J Psychopharmacol, 2026.
  2. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.. BMJ, 2024.
  3. Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.. Acta Psychiatr Scand, 2025.
  4. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.. JAMA Psychiatry, 2026.
  5. Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.. JAMA Netw Open, 2025.
  6. Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis.. Neurosci Biobehav Rev, 2026.